Please use this identifier to cite or link to this item:
|Title:||Assessing 225Ac-Polymersomes for Targeted Radionuclide Therapy|
|Authors:||DE KRUIJFF R. M.; HESKAMP SANDRA; VAN DER MEER A; KOUWENBERG J; TORRELO VILLA G; MORGENSTERN ALFRED; BRUCHERTSEIFER FRANK; SMINIA P; DENKOVA A.G.|
|Publisher:||European Commission - Joint Research Centre|
|Type:||Articles in periodicals and books|
|Abstract:||To use longer-lived alpha-emitting radionuclides like 225Ac (with multiple alpha particles emitted in its decay chain) in targeted alpha therapy (TAT), it is essential to deal with the recoil problem. One way to do this, is to incorporate the mother nuclide in a nanocarrier, allowing the alpha particles to damage surrounding tumour tissue, but keeping the radioactive daughter nuclides inside. In the present study, polymersomes (nanocarriers composed of amphiphilic block copolymers) have been used to retain the harmful daughters. Ideal vesicle designs were simulated with the Geant4 Monte Carlo simulation package, and the recoil retention of 221Fr and 213Bi was determined in different designs. The best design was subsequently synthesized in the lab, and daughter retention has been compared to the simulations.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.